Abstract
We evaluated the microbiological efficacy of tedizolid compared with that of linezolid against common and emerging pathogens using pooled data from 2 phase 3 trials (NCT01170221 and NCT01421511) in patients with acute bacterial skin and skin structure infections. Patients received tedizolid 200 mg once daily for 6 days (n = 664) or linezolid 600 mg twice daily for 10 days (n = 669). Favorable microbiological outcome in both treatment groups, defined as eradication or presumed eradication at the end of treatment and at the posttherapy evaluation, exceeded 85% for most pathogens, including methicillin-resistant Staphylococcus aureus. Favorable microbiological response was observed for staphylococci and streptococci at tedizolid minimal inhibitory concentration values ≤0.5 mg/L and 0.25 mg/L, respectively. The studies demonstrated positive microbiological outcomes against common pathogens with a 6-day, once-daily regimen of tedizolid phosphate in patients with acute bacterial skin and skin structure infections.
| Original language | English (US) |
|---|---|
| Journal | Diagnostic Microbiology and Infectious Disease |
| DOIs | |
| State | Published - Jan 1 2019 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Microbiology (medical)
- Infectious Diseases
Cite this
Comparison of the microbiological efficacy of tedizolid and linezolid in acute bacterial skin and skin structure infections : pooled data from phase 3 clinical trials. / Corey, Ralph; Moran, Gregory; Goering, Richard V.; Bensaci, Mekki; Sandison, Taylor; De Anda, Carisa; Prokocimer, Philippe.
In: Diagnostic Microbiology and Infectious Disease, 01.01.2019.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Comparison of the microbiological efficacy of tedizolid and linezolid in acute bacterial skin and skin structure infections
T2 - pooled data from phase 3 clinical trials
AU - Corey, Ralph
AU - Moran, Gregory
AU - Goering, Richard V.
AU - Bensaci, Mekki
AU - Sandison, Taylor
AU - De Anda, Carisa
AU - Prokocimer, Philippe
PY - 2019/1/1
Y1 - 2019/1/1
N2 - We evaluated the microbiological efficacy of tedizolid compared with that of linezolid against common and emerging pathogens using pooled data from 2 phase 3 trials (NCT01170221 and NCT01421511) in patients with acute bacterial skin and skin structure infections. Patients received tedizolid 200 mg once daily for 6 days (n = 664) or linezolid 600 mg twice daily for 10 days (n = 669). Favorable microbiological outcome in both treatment groups, defined as eradication or presumed eradication at the end of treatment and at the posttherapy evaluation, exceeded 85% for most pathogens, including methicillin-resistant Staphylococcus aureus. Favorable microbiological response was observed for staphylococci and streptococci at tedizolid minimal inhibitory concentration values ≤0.5 mg/L and 0.25 mg/L, respectively. The studies demonstrated positive microbiological outcomes against common pathogens with a 6-day, once-daily regimen of tedizolid phosphate in patients with acute bacterial skin and skin structure infections.
AB - We evaluated the microbiological efficacy of tedizolid compared with that of linezolid against common and emerging pathogens using pooled data from 2 phase 3 trials (NCT01170221 and NCT01421511) in patients with acute bacterial skin and skin structure infections. Patients received tedizolid 200 mg once daily for 6 days (n = 664) or linezolid 600 mg twice daily for 10 days (n = 669). Favorable microbiological outcome in both treatment groups, defined as eradication or presumed eradication at the end of treatment and at the posttherapy evaluation, exceeded 85% for most pathogens, including methicillin-resistant Staphylococcus aureus. Favorable microbiological response was observed for staphylococci and streptococci at tedizolid minimal inhibitory concentration values ≤0.5 mg/L and 0.25 mg/L, respectively. The studies demonstrated positive microbiological outcomes against common pathogens with a 6-day, once-daily regimen of tedizolid phosphate in patients with acute bacterial skin and skin structure infections.
UR - http://www.scopus.com/inward/record.url?scp=85063566389&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85063566389&partnerID=8YFLogxK
U2 - 10.1016/j.diagmicrobio.2019.01.017
DO - 10.1016/j.diagmicrobio.2019.01.017
M3 - Article
C2 - 30940414
AN - SCOPUS:85063566389
JO - Diagnostic Microbiology and Infectious Disease
JF - Diagnostic Microbiology and Infectious Disease
SN - 0732-8893
ER -